BMO Capital analyst John McNulty raised the firm’s price target on Ingevity (NGVT) to $62 from $56 and keeps an Outperform rating on the shares after its Q2 earnings beat. Despite the solid 21% jump in the stock, the firm sees significant upside ahead for Ingevity as it has reached the inflection point in its earnings and free cash flow, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGVT:
- Ingevity’s Financial Health at Risk Amid Escalating U.S.-China Tariff Tensions
- Ingevity Corporation Reports Mixed Q2 2025 Results
- Ingevity’s Earnings Call: Resilience Amid Challenges
- Ingevity reports Q2 adjusted EPS $1.39, consensus $1.16
- Ingevity affirms 2025 sales outlook $1.25B-$1.40B, consensus $1.33B